| Ytd | -20.65% | |
| 1y | -43.32% |
| Open | 1.21 | Prev Close | 1.23 | Low | 1.20 | High | 1.25 | Mkt Cap | 131.76M |
| Vol | 482.43K | Avg Vol | 1.15M | EPS | -0.36 | P/E | N/A | Forward P/E | -10.41 |
| Beta | 1.16 | Short Ratio | 4.08 | Inst. Own | 70.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.05 | 200-d Avg | 1.20 | 1yr Est | 8.67 |
MXCT News
(Editor’s note: The future prices of benchmark tracking ETFs, and the headline, the lede and the eco
US stock futures mixed, Cisco and MaxCyte report positive earnings, Alibaba and Vishay to release re
MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 m
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.04) per share which beat the analyst consensu
Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which met the analyst consensus
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing ena
MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platfo
MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $29.261 million-$32.512 million to $29.261 m
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen
MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platf
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technolo
MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platfor
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet
Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating a
MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $35.11 million-$37.39 million to $35.11 mill
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensu
Stifel analyst Daniel Arias maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price targe
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensu
Additional Transaction DetailsThe following information is being provided in accordance with the dis
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing ena
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading cell-engineering focused company providing enab
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.11) per share which beat the analyst consensu
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)))), a leading, cell-engineering focused company providing en
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in